DMXL2 and chronic myelogenous leukemia, BCR-ABL1 positive: The expression levels of NME8, DMXL2, SCD, and FBN1 were significantly decreased in CML treatment-remission patients, while the CXXC5 expression level was significantly increased, and they all returned to normal control levels.